©The Author(s) 2023.
World J Gastroenterol. Dec 28, 2023; 29(48): 6208-6221
Published online Dec 28, 2023. doi: 10.3748/wjg.v29.i48.6208
Published online Dec 28, 2023. doi: 10.3748/wjg.v29.i48.6208
Table 3 Univariable analysis of risk factors for the advanced treatment, n (%)
| Variables | 5-ASAs-alone group (n = 113) | Advanced treatment group (n = 53) | P value |
| Age | 0.373 | ||
| < 40 yr | 45 (39.8) | 25 (47.2) | |
| ≥ 40 yr | 68 (60.2) | 28 (52.8) | |
| Sex | 0.054 | ||
| Male | 61 (54.0) | 37 (69.8) | |
| Female | 52 (46.0) | 16 (30.2) | |
| Extent | < 0.001 | ||
| E1 or E2 | 65 (57.5) | 3 (5.7) | |
| E3 | 48 (42.5) | 50 (94.3) | |
| CRP | < 0.001 | ||
| < 5 mg/L | 85 (75.2) | 14 (26.4) | |
| ≥ 5 mg/L | 28 (24.8) | 39 (73.6) | |
| Hb | < 0.001 | ||
| ≥ 110 g/L | 94 (83.2) | 26 (49.1) | |
| < 110 g/L | 19 (16.8) | 27 (50.9) | |
| Truelove and Witts index | < 0.001 | ||
| Mild or moderate | 84 (74.3) | 11 (20.8) | |
| Severe | 29 (25.7) | 42 (79.2) | |
| TIGER score | < 0.001 | ||
| < 317 | 98 (86.7) | 16 (30.2) | |
| ≥ 317 | 15 (13.3) | 37 (69.8) | |
| UCEIS score | < 0.001 | ||
| < 6 | 94 (83.2) | 21 (39.6) | |
| ≥ 6 | 19 (16.8) | 32 (60.4) | |
| MES | < 0.001 | ||
| ≤ 2 | 68 (60.2) | 14 (26.4) | |
| > 2 | 45 (39.8) | 39 (73.6) |
- Citation: Liu XY, Tian ZB, Zhang LJ, Liu AL, Zhang XF, Wu J, Ding XL. Clinical value of the Toronto inflammatory bowel disease global endoscopic reporting score in ulcerative colitis. World J Gastroenterol 2023; 29(48): 6208-6221
- URL: https://www.wjgnet.com/1007-9327/full/v29/i48/6208.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i48.6208